Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab in Refractory Advanced Esophageal Cancer
NCT02971956Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Jan 2017
- Primary completion
- Jul 2019
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in esophageal cancer, sponsored by Dana-Farber Cancer Institute. Primary endpoint: Overall Response Rate. Started Jan 2017; status: completed.
02
Drugs
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on NCT02971956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02971956.